At age 33, something shifts. Not in the mirror—in the methylome. The Grolaux et al. study identified a female-specific epigenetic inflection point at 33, a “crisis” of rapid DNA methylation remodeling prospectively associated with cancer onset and systemic inflammation. This is the first major epigenetic transition after puberty, and it coincides with the clinical reality that female fertility begins its steepest decline in the early thirties.
This is the window. Not the desperate last-minute window of the late thirties, but the plastic, responsive window of the early thirties, when the system can still be recalibrated. And within this window, natural and herbal supplements have a legitimate, evidence-based role—not as miracle cures, but as targeted interventions that improve oocyte quality, support implantation, and reduce the complications that make pregnancy dangerous.
The evidence is not uniform. Some supplements have robust randomized controlled trial data. Others have mechanistic plausibility and preliminary human data. And a third category—popular fertility herbs—have concerning safety signals that make them inappropriate for use during pregnancy or even during conception attempts.
This is the honest, evidence-graded guide.
Part One: The Foundations—Micronutrients with Robust Evidence
Myo-Inositol and D-Chiro-Inositol: The PCOS Workhorse
If there is a single supplement with the strongest evidence for improving fertility outcomes in women with PCOS, it is the inositol combination. A 2025 systematic review and meta-analysis of 17 intervention studies found that myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25–2.15) and the number of top-grade embryos (RR: 1.12, 95% CI: 1.02–1.23) in women with PCOS undergoing assisted reproductive technology.
The ratio matters. Under physiological conditions, the plasma MYO/DCI ratio is maintained at 40:1. In women with PCOS, this ratio drops dramatically—to as low as 0.2:1—contributing to elevated androgen production and impaired oocyte quality. Clinical trials testing different ratios found that the 40:1 combination produced the most significant improvements in metabolic and reproductive parameters.
The mechanism is insulin sensitization. Inositol is a second messenger for insulin action. By restoring the MYO/DCI ratio, it improves insulin sensitivity, reduces hyperandrogenism, and restores spontaneous ovulation. In assisted reproduction, it enhances oocyte and embryo quality, thereby improving clinical pregnancy rates.
Dose: 2,000 mg myo-inositol + 50 mg D-chiro-inositol twice daily (40:1 ratio) is the most commonly studied protocol.
Evidence grade: Strong for PCOS-related infertility. Limited for unexplained infertility.
Coenzyme Q10: The Mitochondrial Protector
CoQ10 is the most evidence-backed supplement for improving oocyte quality in women of advanced maternal age—and “advanced maternal age” in the reproductive literature begins at 35, which means the early thirties are the optimal time to start.
A 2025 systematic review and meta-analysis found that CoQ10 increased oocyte retrieval and live birth rates for women diagnosed with poor ovarian response (OR = 2.28), and increased the pregnancy rate for women diagnosed with poor ovarian response or PCOS (OR = 2.20 and 13.26, respectively). In in vitro maturation studies, CoQ10 increased the oocyte maturation rate (OR = 2.73) and decreased oocyte and chromosome aneuploidy rates (OR = 0.31 and 0.57, respectively) for women of advanced maternal age.
The mechanism is mitochondrial. Oocytes contain the highest mitochondrial density of any cell in the body. Mitochondrial dysfunction is a primary driver of oocyte aging, aneuploidy, and implantation failure. CoQ10 is an essential cofactor in the electron transport chain and a potent antioxidant. It supports mitochondrial function, ovarian reserve, and placental function while reducing obesity-related complications such as preeclampsia and miscarriage.
Dose: The optimal treatment regimen identified in the literature is 30 mg/day for 3 months before controlled ovarian stimulation. Higher doses (200–600 mg/day) are commonly used in clinical practice, but the evidence for the lower dose is specific to the IVF context.
Evidence grade: Strong for poor ovarian response and advanced maternal age. Moderate for PCOS.
Vitamin D: The Hormonal Regulator
Vitamin D is not merely a vitamin. It is a steroid hormone with receptors in the ovary, endometrium, and placenta. Deficiency is associated with impaired follicular development, reduced implantation rates, and increased risk of miscarriage.
The evidence for vitamin D supplementation in fertility is nuanced. A 2026 multicentre, double-blind, placebo-controlled randomized clinical trial published in The BMJ found that vitamin D supplementation (4,000 IU/day) for up to 90 days did not improve live birth rates in women with PCOS undergoing IVF, despite significantly increasing serum 25-OHD levels. However, a meta-analysis involving 2,352 women with infertility showed that moderate daily dosing of vitamin D supplementation can improve the clinical pregnancy rate.
The resolution to this apparent contradiction lies in baseline status and phenotype. Women with adequate 25(OH)D levels are far more likely to experience clinical pregnancies than those with deficiency. Vitamin D supplementation can enhance pregnancy rates by improving PCOS symptoms, menstruation, follicular growth, and weight loss in obese patients with PCOS and vitamin D deficiency.
Dose: 2,000–4,000 IU/day, targeting serum 25-OHD levels of 30–50 ng/mL.
Evidence grade: Moderate for improving pregnancy rates in deficient women. Strong for correcting deficiency. Not effective as a universal fertility intervention in replete women.
Part Two: The Emerging Evidence—Antioxidants and Amino Acids
N-Acetylcysteine (NAC): The Ovulation Enhancer
NAC is a precursor to glutathione, the body’s master antioxidant. Its primary fertility application is in PCOS, where oxidative stress contributes to insulin resistance, hyperandrogenism, and ovulatory dysfunction.
A 2024 study published in the Journal of Ovarian Research examined NAC supplementation in women with PCOS and found improvements in endocrine-metabolic profiles and ovulation induction efficacy. Compared to placebo, NAC seems to increase pregnancy and ovulation rates, but not when compared to metformin. A systematic review found that NAC improved endometrial thickness compared to placebo, though no effect was found for pregnancy-related outcomes.
The evidence for NAC in unexplained infertility is less encouraging. A clinical trial combining NAC with clomiphene showed no improvement in pregnancy rates or miscarriage reduction. NAC has not been associated with fetal harm, but its use in pregnancy should be reserved for specific indications.
Dose: 600 mg/day for 3 months is the most commonly studied protocol.
Evidence grade: Moderate for PCOS-related ovulation induction. Limited for unexplained infertility.
Resveratrol: The Age-Dependent Mitochondrial Agent
Resveratrol is a polyphenol found in red grapes, berries, and Japanese knotweed. It is a mitochondrial-targeted nutraceutical with antioxidant and anti-aging properties, and it has been proposed as an adjuvant to optimize assisted reproductive technology outcomes.
A 2026 systematic review and meta-analysis of 7 studies comprising 3,411 patients found that resveratrol supplementation was associated with higher fertilization rates (MD 2.89; 95% CI 1.68 to 4.10; p<0.01). However, no significant differences were observed in biochemical pregnancy, clinical pregnancy, or live birth rates. Subgroup analysis suggested an increased number of mature oocytes in women under 35 years, whereas women 35 and older showed no consistent benefit.
The age-dependence is critical. Resveratrol appears to work best in younger women—which means the early thirties are the optimal window for its use, if it is used at all.
Dose: Not established. Clinical trials have used a range of doses, typically 500–1,500 mg/day.
Evidence grade: Moderate for fertilization rates in women under 35. Insufficient for pregnancy and live birth outcomes.
Selenium and Zinc: The Trace Element Duo
Selenium and zinc are essential trace elements that play critical roles in female reproductive health through antioxidant defense, thyroid hormone metabolism, and oocyte maturation.
A systematic review of minerals in female fertility found that adequate selenium and zinc status is associated with improved oocyte quality, enhanced embryo development, higher fertilization rates, and reduced miscarriage risk. Selenium deficiency has been implicated in male and female infertility, miscarriage, preeclampsia, fetal growth restriction, preterm labor, gestational diabetes, and obstetric cholestasis.
Zinc is necessary for the formation and maturation of spermatozoa, for ovulation, and for fertilization. During pregnancy, zinc deficiency causes spontaneous abortion and other anomalies. Individuals undergoing IVF displayed lower levels of selenium, zinc, and copper in their serum and follicular fluid compared to control groups.
Dose: Selenium 55–200 mcg/day (as selenomethionine); zinc 15–30 mg/day (as zinc citrate or picolinate).
Evidence grade: Moderate for correcting deficiency. Strong for the role of adequacy in reproductive health.
Part Three: The Herbal Frontier—What Works and What Doesn’t
Ashwagandha (Withania somnifera): The Stress Modulator
Ashwagandha is an adaptogenic herb used in Ayurvedic medicine for stress, sleep, and reproductive health. The evidence for its use in pregnancy is emerging but still preliminary.
A 2026 randomized, comparative, open-label, 12-week study evaluated the efficacy and safety of ashwagandha root extract in pregnant women. The study found that ashwagandha supplementation improved hemoglobin levels, red blood cell quality, perceived stress, and multiple laboratory safety markers. No adverse events or serious adverse events occurred, and laboratory evaluations showed no detrimental effects on hepatic or renal function.
A systematic review of ashwagandha’s teratogenic and abortifacient potentials concluded that toxicological studies in animal models demonstrate high tolerability, with no significant reproductive toxicity observed at doses relevant to human consumption. Human clinical studies show no adverse effects on thyroid function, hormonal balance, or reproductive health. Evidence supporting significant teratogenic or abortifacient activity remains inconclusive.
Important caveat: The tradition of Ayurvedic medicine considers ashwagandha safe during pregnancy, but the Western evidence base is limited. Ashwagandha should be used only under medical supervision during pregnancy.
Dose: 300–600 mg/day of root extract (standardized to 5% withanolides).
Evidence grade: Preliminary evidence for safety and stress reduction in pregnancy. Insufficient for fertility outcomes.
Fennel (Foeniculum vulgare): The Endometrial Thickener
Fennel is a phytoestrogenic herb traditionally used to regulate menstrual cycles and improve fertility. A 2024 interventional study of 60 women (25–35 years) with infertility undergoing clomiphene citrate treatment found that fennel supplementation significantly improved endometrial thickness. The mean endometrial thickness in the intervention group was approximately 1.7 mm greater than in the control group. Fennel with clomiphene citrate increased fertility rates compared to the control group.
Dose: 100–200 mg/day of fennel oral capsules.
Evidence grade: Moderate for improving endometrial thickness in clomiphene-treated women. Limited for pregnancy outcomes.
Chasteberry (Vitex agnus-castus): The Ovulation Regulator
Chasteberry is one of the most widely used herbs for female reproductive disorders. It acts on the pituitary-gonadal axis to reduce prolactin levels, normalize progesterone production, and promote regular ovulation.
A 2017 study evaluated the effects of Vitex agnus-castus extract on the secretory function of the pituitary-gonadal axis and pregnancy rate in patients with premature ovarian aging. The study found that VAC extract stimulated systematic ovulation, stabilized reproductive hormones, and promoted regular menstrual cycles, concluding that it is a “safe and effective herb for medicinal applications in women with premature ovarian aging when used within the established dosage guidelines”.
Critical safety warning: Use of VAC should be avoided during pregnancy or lactation. Preclinical evidence states that the use of chasteberry during pregnancy or while breastfeeding may be unsafe. This is not a supplement to continue after conception.
Dose: 20–40 mg/day of dried extract (standardized to 0.5% agnuside).
Evidence grade: Moderate for ovulation regulation and menstrual cycle stabilization. Contraindicated in pregnancy.
Maca (Lepidium meyenii): The Hormone Balancer
Maca is a Peruvian root vegetable traditionally used to enhance fertility and sexual performance. Animal studies have shown that maca treatment increases uterine weight and litter size in female mice, confirming traditional uses for enhancing female fertility.
For women, the picture is less defined. Smaller studies suggest maca may help regulate menstrual cycles, ease PMS symptoms, and support hormone balance, though this research is still in its early stages. Maca may help the body respond to stress, and lower stress can support ovulation.
Critical safety warning: Maca should be avoided during pregnancy and lactation due to lack of safety and efficacy data.
Dose: 1.5–3 g/day of dried root powder.
Evidence grade: Preliminary for menstrual cycle regulation and hormone balance. Contraindicated in pregnancy.
Part Four: Traditional Chinese Medicine—The Shoutai Wan Protocol
Traditional Chinese medicine has a long history of using herbal formulas for fertility and pregnancy support. The most rigorously studied formula for pregnancy safety is Shoutai Wan, a classic prescription containing Cuscuta sinensis, Sambucus nigra, Dipsaci Radix, and Agaricus blazei.
A 2024 case-control retrospective study of 352 patients undergoing IVF-ET found that Shoutai Wan combined with luteal support treatment significantly decreased the miscarriage rate compared to luteal support alone (P = .001). Critically, Shoutai Wan during pregnancy did not affect fetal birth weight (P = .354), and there were no adverse events reported in the treatment group, confirming the safety of TCM for fetus protection during pregnancy.
A systematic review and meta-analysis of 111 studies found that in randomized controlled trials, prenatal use of certain herbal medicines was associated with the live birth rate (RR=1.14, 95% CI: 1.05-1.24) and a lower risk of birth defects (RR=0.46, 95% CI: 0.22-0.94), primarily among women undergoing assisted reproduction. Reductions in miscarriage were observed among those with threatened or recurrent miscarriage.
Important caveat: Not all Chinese herbs are safe. Some specific herbs—such as almond oil and Glycyrrhiza (with preterm birth), betel quid (with low birth weight), An-Tai-Yin (with musculoskeletal malformations), and Coptidis Rhizoma (with nervous system and genital organ malformations)—may be linked to increased risks. Chinese herbal medicine should be used only under the guidance of a qualified practitioner who is aware of the pregnancy context.
Evidence grade: Moderate for Shoutai Wan in reducing miscarriage in IVF-ET. Strong for the general principle that certain herbal medicines can support pregnancy outcomes.
Part Five: The Safety Protocol
What Not to Take
Vitex agnus-castus (chasteberry): Avoid during pregnancy and lactation. May affect pregnancy rate, live birth rate, and fetal development.
Maca: Avoid during pregnancy and lactation due to lack of safety data.
Red clover, dong quai, and other phytoestrogenic herbs: Theoretical risk of hormonal interference. Avoid during conception attempts and pregnancy.
High-dose vitamin A (retinol): Teratogenic at doses above 10,000 IU/day. Use beta-carotene instead.
Any herbal product without a pregnancy safety profile: The default position should be caution. Herbal medicines are not benign simply because they are natural. Many have documented reproductive toxicity.
The Threshold Protocol for the Early Thirties
For women approaching the age 33 epigenetic threshold, the supplement protocol should be structured in phases:
Preconception (3–6 months before conception):
- Myo-inositol/D-chiro-inositol (40:1 ratio, 2,000/50 mg twice daily) if PCOS.
- CoQ10 (200–600 mg/day) for mitochondrial support.
- Vitamin D (2,000–4,000 IU/day, adjusted to serum levels).
- Omega-3 (1 g/day EPA+DHA).
- Selenium (55–200 mcg/day) and zinc (15–30 mg/day).
- Folate (400–800 mcg/day) or methylfolate for MTHFR variants.
- Chasteberry (if indicated for ovulation regulation, but discontinue upon conception).
During pregnancy:
- Continue vitamin D, omega-3, folate, and prenatal multivitamin.
- Ashwagandha (300–600 mg/day) may be continued under medical supervision for stress and sleep.
- Shoutai Wan (under TCM practitioner supervision) for miscarriage prevention if indicated.
- Discontinue chasteberry, maca, and all herbs without pregnancy safety data.
Conclusion: The Window Is Open
The early thirties are the most plastic and responsive period of adult female reproductive life. The epigenetic architecture is being recalibrated at the age 33 threshold. The ovarian reserve is still substantial. And the interventions that work during this window—inositol for PCOS, CoQ10 for mitochondrial support, vitamin D for hormonal regulation, and targeted herbal support for implantation and early pregnancy—are the most effective of any period in the lifespan.
The evidence is not uniform. Some supplements have robust randomized controlled trial data. Others have preliminary evidence and mechanistic plausibility. And some popular fertility herbs have concerning safety signals that make them inappropriate for pregnancy.
The protocol is clear. Foundation first. Evidence-based supplements second. Herbal support only with qualified supervision. And always, always, the safety of the pregnancy takes precedence over the desire to conceive.
The threshold is real. The window is open. And the interventions that prevent the crossing—or support the crossing when it is desired—are available.
References
Bischoff-Ferrari, H. A., Vellas, B., Rizzoli, R., Kressig, R. W., da Silva, J. A. P., Blauth, M., Felson, D. T., McCloskey, E. V., Watzl, B., Hofbauer, L. C., Felsenberg, D., Willett, W. C., Dawson-Hughes, B., Manson, J. E., Siebert, U., Egli, A., Theiler, R. N., Staehelin, H. B., Freystaetter, G., … & Orav, E. J. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, *5*, 376–385. https://doi.org/10.1038/s43587-024-00793-y
Ding, Y., et al. (2026). Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial. BMJ, *392*, e087438. https://doi.org/10.1136/bmj-2025-087438
Grolaux, R., Jacques, M., Jones-Freeman, B., Horvath, S., Teschendorff, A., & Eynon, N. (2026). Sex-specific nonlinear DNA methylation aging trajectories reveal biomarkers of cancer risk and inflammation. Genome Biology, *27*(1), 2. https://doi.org/10.1186/s13059-026-03952-z
Kamali, F., Mojani-Qomi, M. S., Arbabi Bidgoli, S., Lavasani, Z., & Adineh, M. (2025). Fennel (Foeniculum vulgare) oral capsules improve endometrial thickness in infertile women following clomiphene citrate treatment. European Journal of Obstetrics & Gynecology and Reproductive Biology. Advance online publication.
Li, Q., Miao, C., Lin, F., Zhang, H., & Zhang, Q. (2024). A case-control retrospective study for the effect of Shoutai Wan on IVF-ET pregnancy outcome. Medicine, *103*(1), e36846. https://doi.org/10.1097/MD.0000000000036846
Lu, J. Y., Tu, B. W., Li, R., et al. (2025). Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming. Cell, *188*(21), 5895–5911.e17. https://doi.org/10.1016/j.cell.2025.07.031
Mohammadi, S., et al. (2025). The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies. International Journal of Reproductive BioMedicine, *23*(5), 369–382.
Nordio, M., et al. (2024). Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecological Endocrinology, *40*(1), 2299582. https://doi.org/10.1080/09513590.2023.2299582
Pasquali, R., et al. (2025). Effect of micronutrients on fertility and aneuploidy rates in human conceptions: A systematic review and meta-analysis. Reproductive BioMedicine Online. Advance online publication.
Sharma, A., et al. (2025). N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome. Journal of Ovarian Research, *17*, 217. https://doi.org/10.1186/s13048-024-01531-z
Wang, R., et al. (2025). Resveratrol supplementation and assisted reproduction outcomes: A systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. Advance online publication.
Zhang, Y., et al. (2025). Effects of Ashwagandha (Withania somnifera) root extract in pregnant women: a prospective, randomized, comparative, open-label, 12-week study. Frontiers in Pharmacology, *16*, 1524728. https://doi.org/10.3389/fphar.2025.1524728
Zhao, Y., et al. (2026). Benefits and risks of herbal medicine use during pregnancy on offspring outcomes: A systematic review and meta-analysis of randomized controlled trials and observational studies. Pharmacological Research, *108092*. https://doi.org/10.1016/j.phrs.2026.108092